drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Proposed daratumumab biosimilar by Biocad; a fully human IgG1κ monoclonal antibody targeting CD38 that induces CDC, ADCC, ADCP, apoptosis, and modulates CD38 NADase activity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Daratumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
BCD-264 is a daratumumab biosimilar, a fully human IgG1κ monoclonal antibody targeting CD38. It depletes CD38-expressing cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), can induce apoptosis upon cross-linking, and modulates/inhibits CD38 NADase enzymatic activity.
drug_name
BCD-264
nct_id_drug_ref
NCT05974969